Proceedings of the Tenth International Conference of Drug Regulatory Authorities (ICDRA) - Hong Kong, China, 24 - 27 June 2002
(2002; 166 pages) View the PDF document
Table of Contents
View the documentAbbreviations and acronyms used in this report
Open this folder and view contentsOpening ceremony
Open this folder and view contentsHerbal medicines
Open this folder and view contentsKeynote address
Close this folderSafety of blood-derived products
View the documentQuality and safety of plasma for fractionation
View the documentProcedures for inactivation and removal of viruses
View the documentGMP in blood plasma collection centres
View the documentPlasma fractionation - Brazilian programme of self-sufficiency in blood products
View the documentSafety of blood products in New Zealand
View the documentRegulatory experience in Argentina
View the documentSafety of blood products in the Islamic Republic of Iran
View the documentRecommendations
Open this folder and view contentsAntimicrobial resistance - new initiatives
Open this folder and view contentsHarmonization I
Open this folder and view contentsHarmonization II
Open this folder and view contentsProtection of trial subjects in clinical trials
Open this folder and view contentsRegulating biotechnology products
Open this folder and view contentsRegulatory challenges: health sector reform and drug regulatory capacity
Open this folder and view contentsAccess to drugs and vaccines I
Open this folder and view contentsAccess to drugs and vaccines II
Open this folder and view contentsCounterfeit pharmaceutical products
Open this folder and view contentsHomoeopathy
Open this folder and view contentsSafety monitoring
Open this folder and view contentsE-Commerce
Open this folder and view contentsCurrent topics
Open this folder and view contentsRegulatory challenges of new technologies
View the documentList of participants
View the documentBack cover
 

Regulatory experience in Argentina

Dr Marina Rossi, Argentina

ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica) is the national regulatory authority in Argentina. It is responsible for ensuring the quality, safety and efficacy of drugs for human use. Although plasma-derived products are considered as pharmaceutical products in Argentina, blood and blood components, are not. The national blood system is responsible for ensuring the quality and safety of blood and plasma used for fractionation. There are two plasma fractionation facilities in Argentina.

Regulations on good manufacturing practices for products derived from human blood or human plasma were prepared in 1997-1998 by ANMAT, based on the guidelines established by WHO and the European Union. The document consists of two parts:

1. Good manufacturing practices: general requirements, including recommendations on the manufacture and quality control of plasmaderived products.

2. Guide for inspections of manufacturers and importers of plasmaderived products.


The requirements and inspection items are formated as questions in a checklist. Each question is ranked as imperative, necessary, recommendable or informative. A written inspection report should summarize the main aspects of each inspection, give general information about the facilities, and indicate any deficiencies. Each copy of the report should be signed by the inspectors and the responsible person of the plant. One copy of the report is given to the company.

Depending on the inspectors’ report, the responsible authority may:

• temporarily withdraw an establishment’s licence,
• require approval of the work programme,
• issue a certificate of compliance with GMP.


For imported plasma-derived products, inspection of the importers covers only the following items:

• general information,
• storage areas,
• returned products,
• product recall,
• quality control,
• quality assurance.


Each imported consignment of plasma-derived product should be accompanied by the documentation:

• batch release certificates,
• plasma source certificate,
• criteria used to exclude donors with a risk factor for new variant CJD.


Mercosur/Southern Common Market (1994) is a treaty that establishes a common market between Argentina, Brazil, Paraguay and Uruguay. The Blood Products Commission of Mercosur has prepared some harmonized documents including:

• technical requirements for production and quality control of human plasma products (1999): general requirements (GMP) and quality control of albumin, immunoglobulins, factor VII, factor VIII, factor IX and prothrombin complex; and

• guide for inspection of manufacturers and importers of plasma-derived products (2001).


The above documents will be proposed for approval by each member state.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: March 20, 2014